It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Deciphering genomic architecture is key to identifying novel disease drivers and understanding the mechanisms underlying myeloma initiation and progression. In this work, using the CoMMpass dataset, we show that structural variants (SV) occur in a nonrandom fashion throughout the genome with an increased frequency in the t(4;14), RB1, or TP53 mutated cases and reduced frequency in t(11;14) cases. By mapping sites of chromosomal rearrangements to topologically associated domains and identifying significantly upregulated genes by RNAseq we identify both predicted and novel putative driver genes. These data highlight the heterogeneity of transcriptional dysregulation occurring as a consequence of both the canonical and novel structural variants. Further, it shows that the complex rearrangements chromoplexy, chromothripsis and templated insertions are common in MM with each variant having its own distinct frequency and impact on clinical outcome. Chromothripsis is associated with a significant independent negative impact on clinical outcome in newly diagnosed cases consistent with its use alongside other clinical and genetic risk factors to identify prognosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 University of Arkansas for Medical Sciences, Department of Biomedical Informatics, Little Rock, USA (GRID:grid.241054.6) (ISNI:0000 0004 4687 1637); University of Arkansas for Medical Sciences, Winthrop P. Rockefeller Cancer Institute, Little Rock, USA (GRID:grid.241054.6) (ISNI:0000 0004 4687 1637)
2 NYU Langone Health, Perlmutter Cancer Center, New York, USA (GRID:grid.240324.3) (ISNI:0000 0001 2109 4251)
3 University of Newcastle upon Tyne, Institute of Cellular Medicine, Newcastle, UK (GRID:grid.1006.7) (ISNI:0000 0001 0462 7212)
4 Translational Genomics Research Institute, Integrated Cancer Genomics Division, Phoenix, USA (GRID:grid.250942.8) (ISNI:0000 0004 0507 3225)
5 Sylvester Cancer Center University of Miami, Miami, USA (GRID:grid.26790.3a) (ISNI:0000 0004 1936 8606)
6 Division of Hematology Oncology Indiana University, Indianapolis, USA (GRID:grid.257413.6) (ISNI:0000 0001 2287 3919)